% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rnai_inv rnai_inv Oct 9, 2012 10:56 AM Flag

    Alnylam Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan

    That's unexpected bad news

    1) the company didn't bother to tell us
    2) which claims are lost?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Based on this statement, it looks like this was a positive announcement:

      “We are extremely pleased with the outcome of the invalidation trial which resulted in key claims from the Tuschl II ’895 patent being upheld in Japan. This affirms our belief in the validity of these claims and the groundbreaking nature of the Tuschl II invention forming the basis of this critical patent family,” said Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer at Alnylam. “Tuschl II remains a valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee. We look forward to the continued advancement of the Tuschl II patent family worldwide in conjunction with many other Alnylam-held patents and pending patent applications.”

119.87+5.66(+4.96%)Jun 30 4:00 PMEDT